Author Archives: Ana de Barros PhD

BioMarin Launches ‘RARE Scholars’ Scholarship Program for Students with Batten, Other Rare Diseases

BioMarin recently announced the launch of RARE Scholars, an annual scholarship program for students with certain rare diseases, including Batten disease, who demonstrate strong academic performance, leadership skills, and participation in school and community activities. The program is designed to assist high school seniors, graduates, current postsecondary undergraduates, or…

CLN2 Therapy Brineura Gets WORLDSymposium 2018 New Treatment Award

Brineura (cerliponase alfa), marketed by BioMarin Pharmaceuticals, was given the WORLDSymposium 2018 New Treatment Award in recognition of its achievements in treating lysosomal diseases, including Batten disease. Brineura slows the decline of children’s ability to crawl or walk, and is the only therapy approved by the U.S. Food and Drug…